NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-.

Cover of LiverTox

LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet].

Show details

Tolterodine

Last Update: July 7, 2017.

OVERVIEW

Introduction

Tolterodine is an anticholinergic agent used to treat urinary incontinence and hyperactive bladder syndrome. Tolterodine has not been implicated in causing liver enzyme elevations or clinically apparent acute liver injury.

Background

Tolterodine (tol ter' oh deen) is a synthetic anticholinergic and antispasmotic agent that inhibits muscarinic actions of acetylcholine on autonomic nerve endings, decreasing secretions and inhibiting gastrointestinal and bladder motility. Tolterodine increases bladder capacity and decreases bladder contractions and the urgency of urination. Tolterodine was approved for use in the United States in 1998 and indications include urge incontinence and overactive bladder syndrome, including symptoms of urinary urgency and frequency. Tolterodine is available in tablets of 1 and 2 mg and as extended release capsules of 2 and 4 mg in generic forms and under the brand name Detrol. The recommended adult oral dose is 2 to 4 mg daily. Common side effects are those of parasympathetic stimulation and include dryness of the mouth and eyes, decreased sweating, headache, visual blurring, constipation, urinary retention, restlessness, confusion and hallucinations. Anticholinergic agents can precipitate acute narrow angle glaucoma and acute urinary retention.

Hepatotoxicity

Like other anticholinergic agents, tolterodine has not been linked to episodes of liver enzyme elevations or clinically apparent liver injury. A major reason for its safety may relate to the low daily dose. Tolterodine is metabolized in the liver via the cytochrome P450 system (CYP 2D6).

References on the safety and potential hepatotoxicity of anticholinergics are given together after the Overview section on Anticholinergic Agents.

Drug Class: Anticholinergic Agents

PRODUCT INFORMATION

REPRESENTATIVE TRADE NAMES

Tolterodine – Generic, Detrol®

DRUG CLASS

Anticholinergic Agents

COMPLETE LABELING

Product labeling at DailyMed, National Library of Medicine, NIH

CHEMICAL FORMULA AND STRUCTURE

DRUGCAS REGISTRY NUMBERMOLECULAR FORMULASTRUCTURE
Tolterodine124937-51-5C22-H31-N-O
Tolterodine Chemical Structure

Views

Similar articles in PubMed

  • Review Fesoterodine[LiverTox: Clinical and Researc...]
    Review Fesoterodine
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Darifenacin[LiverTox: Clinical and Researc...]
    Review Darifenacin
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Trospium[LiverTox: Clinical and Researc...]
    Review Trospium
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Solifenacin[LiverTox: Clinical and Researc...]
    Review Solifenacin
    . LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. 2012
  • Review Which anticholinergic drug for overactive bladder symptoms in adults.[Cochrane Database Syst Rev. 2012]
    Review Which anticholinergic drug for overactive bladder symptoms in adults.
    Madhuvrata P, Cody JD, Ellis G, Herbison GP, Hay-Smith EJ. Cochrane Database Syst Rev. 2012 Jan 18; 1:CD005429. Epub 2012 Jan 18.
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...